

January 21, 2020

Stayble strengthens its scientific advisory board with US-focused key opinion leaders

Stayble Therapeutics today announced that the company's continue to strengthen its scientific advisory board with two new members – Dr. Aaron Calodney and Dr. Douglas Beall. Their respective expertise and experience within spine-related issues and pain management adds important insights as well as US perspectives.

"We are very excited about Stayble getting more access to international expertise in our research area particularly with a US perspective. Not only is the US a key market for us, but there is an incredible drive for medical innovation that it is key for us to tap into to continue to build a strong scientific presence and, ultimately, increase market interest," says CEO Andreas Gerward.

Anders Lehmann, Chief Scientific Officer comments: "To recruit top experts of this caliber to our scientific advisory board is a recognition of trust in the potential of our technology and drug candidate STA363 from medical key opinion leaders working daily with patients suffering from chronic lower back pain. It is an important validation that we are developing a treatment that is projected to make a significant difference to patients, medical care providers and payors."

Aaron Calodney, MD, is Director of Clinical Research at Precision Spine Care, Tyler, TX, USA and Past President of the American Society of Interventional Pain Physicians (ASIPP). Dr. Calodney serves on the Advisory Board for the World Institute of Pain (WIP). He has served on the Board of Directors and as Chairman of Education for the International Spine Intervention Society (ISIS) where he is a Master Instructor. Dr. Calodney is also a lecturer and examiner for the American Board of Interventional Pain Physicians (ABIPP), and the Fellow of Interventional Pain Practice (FIPP) certifying examinations. Dr. Calodney is board certified in Anesthesiology and carries subspecialty certification in Pain Management through the American Board of Anesthesiology.

With particular interest in Spine and special interests including Neuromodulation and Intrathecal Drug Delivery, Biological treatment of the painful degenerative disc, Peripheral nerve injury, and Radiofrequency ablation, Dr. Calodney has presented and published many articles and textbook chapters. He is actively involved in clinical research and has delivered over 400 invited lectures in the US and abroad. He is an author of the first Evidenced Based Treatment Guidelines in Interventional Pain, Evidenced Based Guidelines for the Use of Opioids, and guidelines for the use of regenerative medicine in the lumbar spine.

Douglas Beall, MD, is Chief of Interventional Spine Services and Chief of Radiology Services at Clinical Radiology of Oklahoma, Oklahoma City, OK, USA. In addition to expertise in Musculoskeletal Imaging and Interventional Spine Care, Dr. Beall is a Diplomate of the American Academy of Pain Management, a Fellow of the Society of Interventional Radiology and a Fellow of Interventional Pain Practice.

He is actively involved in teaching and research, publishing more than 250 articles in peer-reviewed journals, 6 textbooks, 60 textbook chapters, and more than 1000 invited lectures and scientific presentations. Dr. Beall is a member of the Editorial Advisory Board of Diagnostic Imaging, and Reviewer for the Musculoskeletal Section of the American Journal of Roentgenology. Dr. Beall has also been Involved In several clinical trials on new interventions in discogenic low back pain.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

andreas.gerward@stayble.se,

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se. More information on www.staybletherapeutics.com.